Novel Immunotherapies and Combinations

(25:34)

Novel immunotherapy approaches for MMR-proficient colorectal cancer

(49)

Novel immunotherapy and small molecule inhibitor combinations

(2:14)

Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma

(1:4)

Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies

(56:13)

Dr. Zamarin on Novel Immunotherapy Approaches in Gynecologic Cancers

(1:5)

Novel immunotherapy combinations for SCLC

(5:43)

Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies

(55:13)

Localized gemcitabine delivery in low-grade upper tract urothelial carcinoma

(1:52)

Advanced Gastroesophageal Cancers: Maximizing the Benefits of Novel Immunotherapy Approaches

(47:55)

Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment

(8:25)

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

(55)

Novel Immunotherapy Combinations in NSCLC

(7:)

Novel immunotherapy-based combination approaches in cervical cancer

(1:19)

Novel Immunotherapy Combinations for NSCLC

(2:20)

The Future of Novel Immunotherapy Combinations in Melanoma

(1:29)

Benjamin Weinberg on Novel Immunotherapy for Pancreatic Cancer | ASCO 2024

(3:22)

Dr. Sabari on Novel Immunotherapy Combos Under Investigation in NSCLC

(1:35)

A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint | David McDermott

(4:4)

Novel immunotherapy decoy-resistant IL-18 for the treatment of renal cell carcinoma

(3:49)